Pepti Review: $109 Semaglutide, 28-Day Billing

Pepti (hellopepti.com) sells compounded semaglutide at $109 and tirzepatide at $179, with the consultation and the shipping inside the figure and no plan ladder to decode. Read live on 1 September 2026, both prices sit on three separate surfaces a buyer can transact from, which is what makes them checkable rather than a claim.¹ Two things sit underneath them, and on a savings desk both belong above the fold.

A month here is 28 days

Pepti's billing terms say so plainly, and they deserve credit for it: the charge lands on the cycle the supply lasts, measured in days rather than on a calendar date, and it "can bill twice in the same calendar month". Twenty-eight-day billing comes round thirteen times a year. So $109 is about $1,417 a year rather than $1,308, and $179 is about $2,327 rather than $2,148 — roughly $109 and $179 more than a monthly framing implies, which is to say one extra charge each.

The product pages still call the figure an "ALL-IN MONTHLY PRICE". The word all-in survives the check; the word monthly does not.

Two of its own pages print older prices

The cost page for semaglutide prints $79 and, in the same breath on the same page, says pricing is kept "flat and transparent at $109". The tirzepatide cost page prints $149 while every other surface says $179. Three transactable surfaces agree on $109 and $179, so those are the figures this review carries — but a shopper who lands on a cost page first will read a number that is $30 low on one molecule and $30 low on the other.

What happened to the August caveat

The August version of this review led on something we could not resolve: a per-dose price ladder running $299 to $449 for semaglutide and $349 to $549 for tirzepatide, sitting in Pepti's own server payload, rendered by nothing on the site and reachable through no surface we could find. We could not break the tie at the checkout, so we published it as an open question rather than as a finding.

On the 1 September read that ladder did not reappear, and the transactable prices had moved to $109 and $179. **We did not census the payload again, so this is the absence of a reproduction, not a confirmed removal**, and it is written that way on purpose. What it means practically has not changed: read the figure on your order confirmation before your card is charged a second time.

When you are actually charged

Payment is taken at the checkout, before a physician reviews the intake, and the refund is the remedy if you are declined. The marketing says only that it is free to start with no enrollment fee. A money-back chip on the product pages has no matching clause anywhere in the published refund policy.

Cancellation is straightforward and stated once: cancel from the account at any time, all future charges stop, and a supply already shipped is not refunded.

50 states and D.C., not 36

This has changed since August, and in the right direction. The site now publishes all 50 states plus Washington, D.C. — its own page labels that "51 states", which is 50 states and a district, but the coverage itself is the widest it publishes and it is published as a list rather than as an unqualified nationwide claim.

Who is prescribing, and who is compounding

Two physicians are named with full biographies and board certifications — Dr. Gene Lee, family medicine, and Dr. Laeeq Butt. Neither publishes an identifier that can be checked against the federal registry, so neither can be verified from outside.

A dispensing partner is now named where none was in August: the Pharmacy Fulfillment Policy says prescriptions are fulfilled by "Olympia". One name, with no legal entity, no state and no address attached to it, on a page that also says the fulfilling pharmacy varies per patient and that partners may change. At $109 a month that gap deserves more weight than it would at $299 — the whole argument of is cheap compounded GLP-1 safe? is that a low price is a reason to check the supply chain harder, and how to verify a compounding pharmacy is legitimate is the check that a bare first name makes hard to run.

The corporate address is a Newark, Delaware suite that is a shared registered-agent address rather than a clinical office.

Labs, and the badge

Baseline labs are included only "if required" by a doctor, with a deeper panel at $149 and a monthly bloodwork plan at $129 beside it. That is a conditional inclusion rather than the flat one the trust bar implies.

The homepage trust cluster carries an "FDA CLEARED" badge while the product pages correctly state that compounded medications are not approved by the FDA. What the badge refers to is not explained anywhere on the site.

In August its shelf also carried retatrutide, melanotan II and IGF-1 LR3, none of which belongs on a shortlist — retatrutide has no FDA approval in any form anywhere, and the reasons are laid out in is retatrutide available, and is it safe to buy now?. We did not re-census the peptide shelf on 1 September, so treat that as an August observation rather than a current one.

The regulatory screen

The trading name and the legal entity both returned zero company-column matches in the FDA's live warning-letter index.² The pass carried a positive control that correctly returned a known letter for an unrelated seller, so the zero is evidence rather than a failed query.

The verdict for a bargain hunter

$109 all-in is genuinely cheap, and it is cheap in the way that matters: no plan term, no introductory month, no membership bolted alongside. Budget thirteen charges a year rather than twelve, ignore the two cost pages that still print $79 and $149, and ask who Olympia is before your first refill. Then check it against the semaglutide price ladder and the rest of our research.